Financials
Financial year 2025
Emma® Nutrition from Poperinge, company number BE0424941459, closed financial year 2025 with a result of € 122,783 after tax. For that financial year Emma® Nutrition recorded a gross margin of € 254,652 and equity of € 431,941. Compared with financial year 2024, the result moved from € 150,597 to € 122,783. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.
€ 431,941
▲ 39% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 122,783
▼ 18% vs 2024
Profit after tax over the fiscal year.
€ 120,521
▲ 220% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 385,172.
People and assets in 2025
1.4
▲ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 58,594
▲ 7% vs 2024
€ 41,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 32,017
▼ 21% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 3,053
▼ 39% vs 2024
€ 2,012 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 62,690
▲ 20% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 31,913
▼ 17% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 61,276 | € 215,416 | € 277,536 | € 254,652 | ▼ 8% |
| Profit after taxes | € 1,638 | € 109,449 | € 150,597 | € 122,783 | ▼ 18% |
| Equity | € 48,376 | € 161,394 | € 311,091 | € 431,941 | ▲ 39% |
| Total debts | € 143,106 | € 141,998 | € 108,582 | € 101,111 | ▼ 7% |
| Cash | - | - | € 37,675 | € 120,521 | ▲ 220% |
| Retained profit | € 3,376 | € 112,825 | € 263,422 | € 385,172 | ▲ 46% |
| Bank debt | € 38,223 | € 27,886 | € 4,995 | € 3,053 | ▼ 39% |
| Balance sheet total | € 191,482 | € 303,392 | € 419,673 | € 534,085 | ▲ 27% |
| Employees (FTE) | 1.1 | 1.1 | 1.1 | 1.4 | ▲ 0.3 |
Key figures of Emma® Nutrition, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Emma® Nutrition?
What happened at Emma® Nutrition in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 122,783 (▼ 18% vs 2024). Source: NBB ↗
- Maurice Verschaeve became a director. NBB
- Laura Grouset became a director. NBB
- New establishment in Poperinge. KBO
- Start of the company according to the CBE. KBO
In short
From € 1,638 profit in 2022 to € 122,783 profit in 2025.
Paid € 143,640 in corporate taxes since 2022.
Best year ever: 2024, with € 150,597 profit.
On average € 181,900 of value added per employee in 2025.
Management
Behind Emma® Nutrition are Maurice Verschaeve and Laura Grouset. The same people are also behind KPL & C°.
Establishments
Establishment units
Physical locations of this company
Paardenmarkt 10
8970 Poperinge
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0424.941.459
- VAT number
- BE 0424.941.459
- Registered office
- Paardenmarkt 10, 8970 Poperinge
- Names & denominations
- Emma® Nutrition
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 December 1983
- Peppol
- Active · Active since 21 Oct 2026
- Activities · NACE
Groothandel in chemische producten voor industrieel gebruik
Groothandel in chemische producten
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten